New Guidance on Chronic Insomnia Treatment

Experts recommend CBT-I as first-line therapy, with combination treatment reserved for selected patients

By
Conexiant News Staff
April 15, 2026
4 min

Conexiant

Overview

The American Academy of Sleep Medicine (AASM) guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as the preferred first-line treatment for chronic insomnia. Combination therapy with CBT-I and pharmacotherapy offers modest benefits over medication alone but does not improve outcomes compared to CBT-I alone.

Background

Chronic insomnia disorder affects many adults and requires effective management strategies. Treatment options include cognitive behavioral therapy for insomnia (CBT-I), pharmacotherapy, or a combination of both. The AASM conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the comparative effectiveness of these approaches. This guideline aims to clarify the role of combination therapy relative to established treatments.

Data Highlights

Comparison	Outcome	Effect	Adverse Effects
Combination therapy vs Pharmacotherapy alone	Global insomnia severity, sleep continuity	Small, clinically meaningful improvements	Slightly higher rates, especially morning sleepiness
Combination therapy vs CBT-I alone	Insomnia severity, sleep continuity, daytime functioning	No clinically meaningful improvements	Not specified
Combination therapy (short-term)	Total sleep time (TST)	Short-term increase noted	Not clinically meaningful in other outcomes

Key Findings

CBT-I remains the preferred first-line treatment for chronic insomnia.
Combination therapy provides modest benefits over pharmacotherapy alone but no meaningful improvement over CBT-I alone.
Combination therapy is associated with slightly increased adverse effects, particularly morning sleepiness.
Pharmacotherapy alone is appropriate when CBT-I is unavailable, unaffordable, or not feasible.
Shared decision-making is emphasized to tailor treatment based on patient preferences, clinical priorities, and access.
Evidence is limited by low certainty, short-term outcomes, and underrepresentation of diverse populations.

Clinical Implications

Clinicians should prioritize CBT-I as the first-line treatment for chronic insomnia, reserving combination therapy for patients needing rapid symptom relief or short-term increases in total sleep time. Pharmacotherapy alone remains a reasonable option when CBT-I cannot be accessed or tolerated. Shared decision-making is essential to balance effectiveness, patient preferences, and treatment availability.

Conclusion

The AASM guideline supports CBT-I as the cornerstone of chronic insomnia management, with combination therapy offering limited additional benefit over CBT-I alone. Treatment should be individualized, considering patient needs and access to care.